Robert Sandhaus
Pulmonary Disease · Denver, CONPI 1093884652
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by CSL Behring at 44.5% of the total. Reporting peaked in 2020 at $27,904 and has fallen 71.5% since, to $7,964 in 2025. Among pulmonary disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $1225.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$45K
- Grifols USA, LLC$17K
- Sanofi$15K
- Grifols Shared Services North America, Inc.$7K
- GSK$5K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- plus $8K from 5 others
Across 7 payments — averaging $14,477 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$96K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
What the payments were for
- Consulting fees$48,18947%
- Speaking & faculty fees$38,77638%
- Travel & lodging$12,73513%
- Food & beverage$1,9702%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 21 | $45,272 |
| Grifols USA, LLC | 21 | $17,304 |
| Sanofi | 6 | $14,907 |
| Grifols Shared Services North America, Inc. | 8 | $6,816 |
| GSK | 1 | $4,550 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $4,460 |
| Grifols Canada Ltd. | 3 | $3,600 |
| Astrazeneca AB | 4 | $3,150 |
| Vertex | 7 | $1,334 |
| Vifor Pharma, Inc. | 6 | $183 |
| Regeneron Healthcare Solutions, Inc. | 1 | $102 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zemaira$34,960
- Prolastin-C Liquid$23,396
- GLASSIA$4,416
- Veltassa$118
- DUPIXENT$102
How this compares
$101,678 in reported general payments places this provider in the 90th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Denver
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
- Barry MakeDenver$162K
- Amy OlsonDenver$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.